Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $28.05 | Total: $140.25 |
| 1 | 10 | $23.76 | Total: $237.60 |
| 1 | 25 | $20.13 | Total: $503.25 |
| 1 | 50 | $17.16 | Total: $858.00 |
| 1 | 100 | $14.85 | Total: $1,485.00 |
Overview
Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate) is a broad-spectrum antifungal agent approved in Japan for treating onychomycosis, a fungal nail infection. It is a prodrug converted into ravuconazole.
Chemical Properties
| Molecular Formula | C31H40F2N7O8PS |
| Molecular Weight | 739.7 |
| CAS Numbers | 914361-45-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | N#CC1=CC=C(C2=CSC([C@H](C)[C@@](OCOP(O)(O)=O)(C3=CC=C(F)C=C3F)CN4N=CN=C4)=N2)C=C1.CCO.N[C@H](C(O)=O)CCCCN |
Storage and Handling
0C Short Term, -20C Long Term
References
Diniz LF, Mazzeti AL, Caldas IS, Ribeiro I, Bahia MT. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018;62[6] e00401-18. Published 2018 May 25. doi 10.1128AAC.00401-18Watanabe S, Tsubouchi I, Okubo A. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis A multicenter, double-blind, randomized phase III study. J Dermatol. 2018;45[10] 1151-1159. doi 10.11111346-8138.14607